Market access growth Petauri Evidence is expanding through strategic hires in market access, pricing, and operations (e.g., Chris Stewart, Kim Cline, Sam Davies), signaling a scalable opportunity to deepen engagement with pharma and medtech clients seeking end-to-end market access solutions.

Integrated platform leverage As a dedicated unit within a broader pharmaceutical services platform, Petauri Evidence offers integrated capabilities from evidence generation to reimbursement communication, presenting a compelling upsell path for clients needing cohesive, cross-functional support.

Global and local reimbursement focus The emphasis on national, regional, and local reimbursement and formulary inclusion provides a clear angle to target firms facing multi-jurisdictional access hurdles and pricing strategies requiring expert HEOR and value communication.

Recognition and credibility Recent industry recognitions (MM+M Agency 100 2026) and high-profile leadership appointments bolster credibility, enabling stronger outreach to prospective clients aiming to partner with a proven market access and evidence-generation partner.

Growth through acquisitions The formation of Petauri Evidence via the integration of Mtech Access and Delta Hat under the Petauri platform indicates a dynamic M&A-enabled expansion strategy, suggesting opportunities to approach similar firms seeking accelerated market access capabilities.